Bridging the Gender Gap in Diagnostics

How Exazym? Can Improve Troponin Measurements for Women

Heart disease is the number one cause of death in women worldwide, often presenting with different symptoms in women than in men. That’s why when it comes to heart attack diagnosis, one size does not fit all. Recent research has highlighted how, in addition to presenting with different symptoms than men, many women also have lower baseline levels of key biomarkers, such as troponin. This can lead to underdiagnosis or delayed treatment, putting women at greater risk for severe complications.

At Cavidi, we understand the critical role of accurate and sensitive biomarker detection in improving patient outcomes. That’s why we developed Exazym?,? a game-changing innovation in precision health that makes ultra-sensitive detection levels possible for any laboratory.

Exazym? is an add-on immunoassay reagent kit that requires no additional specialized equipment and can be easily added to existing immunoassay workflows.? Exazym? is based on a new detection method called Binding Oligo Ladder Detection, or BOLD for short. This new amplification technique is ideally suited for detecting low-abundance analytes. Exazym? can help laboratories and clinicians achieve more accurate results for patients with lower baseline biomarker levels. Troponin testing for heart attack detection in women is an excellent case in point.

The Challenge: Women and Lower Baseline Biomarker Levels

Women generally have lower levels of troponin than men, making it more difficult to detect heart damage in its early stages. A study published in Pathology found that peak troponin levels in female hospital patients were four times lower than in men. Since many diagnostic thresholds have historically been based on male populations, women may not receive timely or appropriate treatment.

Beyond cardiology, this issue extends to other critical biomarkers used for diagnosing diseases and monitoring treatment efficacy. The need for greater sensitivity in diagnostic assays is clear—especially for conditions where early detection can save lives.

How Exazym? Enhances Low-Abundance Biomarker Detection

Cavidi’s Exazym? technology provides a highly sensitive signal amplification system that enhances the detection of biomarkers at very low concentrations. This means:

• Better detection of critical biomarkers in patients with low baseline levels, ensuring that no vital health indicator is overlooked.
• Improved assay performance, allowing clinicians to make more confident and timely treatment decisions.
• Optimized accuracy in diverse patient populations, including women, who may require more precise measurement tools to ensure proper diagnosis and treatment.

The Future of Precision Diagnostics for Women

Advancements in biomarker detection, like Exazym?’s BOLD technology, are crucial for closing the gender gap in diagnostics. By improving measurement accuracy in individuals with lower baseline biomarker levels, we can ensure that women receive the timely and effective care they need.

At Cavidi, we are committed to advancing diagnostic tools that enhance sensitivity, accuracy, and accessibility—because every patient deserves the best possible care.

If you would like to learn more about how Exazym? can elevate your diagnostic assays, please feel free to contact us.

This post was originally published on our blog.

Photo by Modestas Urbonas on Unsplash